Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RXIM002 in Relapsed or Refractory Autoimmune Cytopenias
NCT07765966Phase 1Not yet recruiting
- Sponsor
- RiboX Therapeutics
- Start
- Feb 2027
- Primary completion
- Jun 2028
01
Overview
Phase 1, open-label, single-arm trial of RXIM002 in immune thrombocytopenia (ITP), sponsored by RiboX Therapeutics. Primary endpoints: Incidence of treatment-emergent adverse events at 104 weeks and Dose-limiting toxicities at 28 days. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
RXIM002
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07765966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07765966.